{"analyses":[{"ciLowerLimit":"0.553","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.790","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","pValueComment":"All analyses based on final database lock (DBL) were descriptive only with p-values reported as nominal.","paramType":"Hazard Ratio (HR)","paramValue":"0.661","statisticalMethod":"Stratified log-rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"19.4","upperLimit":"27.6","value":"23.4"},{"groupId":"OG001","lowerLimit":"11.2","upperLimit":"16.2","value":"13.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"357"},{"groupId":"OG001","value":"355"}],"units":"Participants"}],"description":"OS was defined as the time from randomization to the date of death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received cemiplimab monotherapy","id":"OG000","title":"Cemiplimab"},{"description":"Participants received platinum-based doublet chemotherapy","id":"OG001","title":"Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"FAS included all randomized participants.","reportingStatus":"POSTED","timeFrame":"Up to 94 months","title":"Overall Survival (OS)","type":"PRIMARY","unitOfMeasure":"months"}